GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
INR 2303.2
(-1.26%)
INR 2303.2
(-1.26%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 6.75 Billion | 4.84 Billion | 8.1 Billion | 5.77 Billion | 4.9 Billion | 3.99 Billion |
| Net Income | 5.89 Billion | 8.41 Billion | 24.75 Billion | 7.23 Billion | 6.47 Billion | 6.53 Billion |
| Depreciation & Amortization | 695.35 Million | 657.7 Million | 681.86 Million | 792.83 Million | 826.77 Million | 485.9 Million |
| Deferred income taxes | - | -25.33 Million | -65.44 Million | -128.5 Million | -132.11 Million | -77.45 Million |
| Stock-based compensation | 113.97 Million | 25.33 Million | 65.44 Million | 128.5 Million | 132.11 Million | 77.45 Million |
| Change in working capital | 610.2 Million | -457.4 Million | 1.19 Billion | 457.6 Million | 440.68 Million | -41.92 Million |
| Other non-cash items | -10.12 Million | -3.77 Billion | -18.52 Billion | -2.7 Billion | -2.83 Billion | -2.98 Billion |
| Investing Cash Flow | -847.2 Million | 8.07 Billion | -4.05 Billion | 4.18 Billion | -568.43 Million | -1.43 Billion |
| Investments in PPE | -312.21 Million | -440.4 Million | -346.41 Million | -442.26 Million | -1.55 Billion | -2.91 Billion |
| Acquisitions | 44.69 Million | 1.94 Billion | 335.19 Million | 1.8 Billion | 1.55 Billion | 2.91 Billion |
| Investment purchases | -58.02 Billion | -52.64 Billion | -30.69 Billion | -33.78 Billion | -11.41 Billion | -12.41 Billion |
| Sales/Maturities of investments | 56.78 Billion | 62.2 Billion | 12.57 Billion | 36.03 Billion | 12.33 Billion | 12.61 Billion |
| Other Investing Activities | 654.82 Million | -2.98 Billion | 14.07 Billion | 578.18 Million | -1.48 Billion | -1.63 Billion |
| Financing Cash Flow | -5.61 Billion | -15.43 Billion | -5.24 Billion | -6.96 Billion | -4.27 Billion | -3.58 Billion |
| Debt repayment | -181.3 Million | -168.67 Million | -240 Thousand | -1.53 Million | -4.06 Million | -4.06 Million |
| Dividends payments | -5.41 Billion | -15.25 Billion | -5.06 Billion | -6.77 Billion | -4.08 Billion | -2.96 Billion |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -17.9 Million | -178.3 Million | -175.83 Million | -183.62 Million | -884.03 Million | -614.92 Million |
| Accounts receivables | -302.68 Million | 202.28 Million | 102.04 Million | -999.34 Million | -497 Thousand | 268.91 Million |
| Accounts payables | 1.9 Billion | -1.53 Billion | 1.02 Billion | 1.07 Billion | -482.29 Million | -1 Billion |
| Inventory | -650.77 Million | 747.2 Million | 120.02 Million | -467.93 Million | -677.16 Million | 136.89 Million |
| Other working capital | -337.69 Million | 125.26 Million | -47.09 Million | 850.77 Million | 1.6 Billion | 552.66 Million |
| Cash at beginning of period | 550.38 Million | 2.86 Billion | 4.05 Billion | 1.04 Billion | 987.76 Million | 2.01 Billion |
| Cash at end of period | 860.76 Million | 349.4 Million | 2.86 Billion | 4.05 Billion | 1.04 Billion | 987.76 Million |
| Capital Expenditure | -312.21 Million | -440.4 Million | -346.41 Million | -442.26 Million | -1.55 Billion | -2.91 Billion |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 310.37 Million | -2.51 Billion | -1.19 Billion | 3 Billion | 60.34 Million | -1.02 Billion |
| Free Cash Flow | 6.44 Billion | 4.4 Billion | 7.76 Billion | 5.33 Billion | 3.34 Billion | 1.08 Billion |
| Breakdown | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 1.82 Billion | 1.94 Billion | 5.89 Billion | 457.2 Million | 2.17 Billion | 1.32 Billion |
| Depreciation & Amortization | - | - | 695.35 Million | 171.1 Million | 181.1 Million | 163.6 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | 113.97 Million | 113.97 Million | - | - | - |
| Change in working capital | - | - | 610.2 Million | - | - | - |
| Other non-cash items | -1.82 Billion | -2.05 Billion | -10.12 Million | -457.2 Million | -2.17 Billion | -1.32 Billion |
| Investing Cash Flow | - | - | -847.2 Million | - | - | - |
| Investments in PPE | - | - | -312.21 Million | - | - | - |
| Acquisitions | - | - | 44.69 Million | - | - | - |
| Investment purchases | - | - | -58.02 Billion | - | - | - |
| Sales/Maturities of investments | - | - | 56.78 Billion | - | - | - |
| Other Investing Activities | - | - | 654.82 Million | - | - | - |
| Financing Cash Flow | - | - | -5.61 Billion | - | - | - |
| Debt repayment | - | - | -181.3 Million | - | - | - |
| Dividends payments | - | - | -5.41 Billion | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | -17.9 Million | - | - | - |
| Accounts receivables | - | - | -302.68 Million | - | - | - |
| Accounts payables | - | - | 1.9 Billion | - | - | - |
| Inventory | - | - | -650.77 Million | - | - | - |
| Other working capital | - | - | -337.69 Million | - | - | - |
| Cash at beginning of period | - | - | 550.38 Million | 10.91 Billion | 10.55 Billion | 550.38 Million |
| Cash at end of period | - | - | 860.76 Million | 11.25 Billion | 10.91 Billion | 877.58 Million |
| Capital Expenditure | - | - | -312.21 Million | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | 310.37 Million | 342.2 Million | 362.2 Million | 327.2 Million |
| Free Cash Flow | - | - | 6.44 Billion | 342.2 Million | 362.2 Million | 327.2 Million |
UREQF
3363
ATAZF
BRPT
ADVWW
TRITURBINE